236 related articles for article (PubMed ID: 33311518)
1. An immune checkpoint score system for prognostic evaluation and adjuvant chemotherapy selection in gastric cancer.
Wang JB; Li P; Liu XL; Zheng QL; Ma YB; Zhao YJ; Xie JW; Lin JX; Lu J; Chen QY; Cao LL; Lin M; Liu LC; Lian NZ; Yang YH; Huang CM; Zheng CH
Nat Commun; 2020 Dec; 11(1):6352. PubMed ID: 33311518
[TBL] [Abstract][Full Text] [Related]
2. An Immune Cell Signature Is Associated With Disease-Free Survival and Adjuvant Chemosensitivity of Patients With Resectable Gastric Cancer.
Yan H; Chen Y; Yang Z; Li Z; Che X; Xiao J; Liu Y; Qu X
Front Immunol; 2020; 11():621623. PubMed ID: 33613554
[TBL] [Abstract][Full Text] [Related]
3. Single Patient Classifier Assay, Microsatellite Instability, and Epstein-Barr Virus Status Predict Clinical Outcomes in Stage II/III Gastric Cancer: Results from CLASSIC Trial.
Roh CK; Choi YY; Choi S; Seo WJ; Cho M; Jang E; Son T; Kim HI; Kim H; Hyung WJ; Huh YM; Noh SH; Cheong JH
Yonsei Med J; 2019 Feb; 60(2):132-139. PubMed ID: 30666834
[TBL] [Abstract][Full Text] [Related]
4. Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit.
Jiang Y; Xie J; Han Z; Liu W; Xi S; Huang L; Huang W; Lin T; Zhao L; Hu Y; Yu J; Zhang Q; Li T; Cai S; Li G
Clin Cancer Res; 2018 Nov; 24(22):5574-5584. PubMed ID: 30042208
[No Abstract] [Full Text] [Related]
5. ImmunoScore Signature: A Prognostic and Predictive Tool in Gastric Cancer.
Jiang Y; Zhang Q; Hu Y; Li T; Yu J; Zhao L; Ye G; Deng H; Mou T; Cai S; Zhou Z; Liu H; Chen G; Li G; Qi X
Ann Surg; 2018 Mar; 267(3):504-513. PubMed ID: 28002059
[TBL] [Abstract][Full Text] [Related]
6. A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy.
Qian J; Qian Y; Wang J; Gu B; Pei D; He S; Zhu F; Røe OD; Xu J; Liu L; Gu Y; Guo R; Yin Y; Shu Y; Chen X
Drug Des Devel Ther; 2016; 10():241-58. PubMed ID: 26966350
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of the infiltration of CD163
Huang X; Pan Y; Ma J; Kang Z; Xu X; Zhu Y; Chen J; Zhang W; Chang W; Zhu J
Cancer Med; 2018 May; 7(5):1731-1741. PubMed ID: 29573574
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Cyclin D1 and CD44 Expression in Gastric Adenocarcinoma.
Ibrahim HM; AbdElbary AM; Mohamed SY; Elwan A; Abdelhamid MI; Ibrahim A
J Gastrointest Cancer; 2019 Sep; 50(3):370-379. PubMed ID: 29497929
[TBL] [Abstract][Full Text] [Related]
9. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
[TBL] [Abstract][Full Text] [Related]
10. Preoperative controlling nutritional status (CONUT) score as a predictor of long-term outcome after curative resection followed by adjuvant chemotherapy in stage II-III gastric Cancer.
Liu X; Zhang D; Lin E; Chen Y; Li W; Chen Y; Sun X; Zhou Z
BMC Cancer; 2018 Jun; 18(1):699. PubMed ID: 29954375
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of a 25-gene assay in patients with gastric cancer after curative resection.
Wang X; Liu Y; Niu Z; Fu R; Jia Y; Zhang L; Shao D; Du H; Hu Y; Xing X; Cheng X; Li L; Guo T; Li Z; Ji Q; Zhang L; Ji J
Sci Rep; 2017 Aug; 7(1):7515. PubMed ID: 28790411
[TBL] [Abstract][Full Text] [Related]
12. Systemic prognostic score and nomogram based on inflammatory, nutritional and tumor markers predict cancer-specific survival in stage II-III gastric cancer patients with adjuvant chemotherapy.
Liu X; Wu Z; Lin E; Li W; Chen Y; Sun X; Zhou Z
Clin Nutr; 2019 Aug; 38(4):1853-1860. PubMed ID: 30075998
[TBL] [Abstract][Full Text] [Related]
13. Tumor-infiltrating Neutrophils is Prognostic and Predictive for Postoperative Adjuvant Chemotherapy Benefit in Patients With Gastric Cancer.
Zhang H; Liu H; Shen Z; Lin C; Wang X; Qin J; Qin X; Xu J; Sun Y
Ann Surg; 2018 Feb; 267(2):311-318. PubMed ID: 27763900
[TBL] [Abstract][Full Text] [Related]
14. Poor clinical outcomes of intratumoral dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin-positive macrophages associated with immune evasion in gastric cancer.
Liu X; Cao Y; Li R; Gu Y; Chen Y; Qi Y; Lv K; Wang J; Yu K; Lin C; Liu H; Zhang H; He H; Chen L; Zhang P; Shen Z; Qin J; Sun Y; Li H; Huang H; Zhang W; Xu J
Eur J Cancer; 2020 Mar; 128():27-37. PubMed ID: 32109848
[TBL] [Abstract][Full Text] [Related]
15. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis.
Kanda M; Murotani K; Kobayashi D; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Surgery; 2015 Dec; 158(6):1573-80. PubMed ID: 26120068
[TBL] [Abstract][Full Text] [Related]
16. Up-regulated Wnt1-inducible signaling pathway protein 1 correlates with poor prognosis and drug resistance by reducing DNA repair in gastric cancer.
Zhang LH; Wang Y; Fan QQ; Liu YK; Li LH; Qi XW; Mao Y; Hua D
World J Gastroenterol; 2019 Oct; 25(38):5814-5825. PubMed ID: 31636474
[TBL] [Abstract][Full Text] [Related]
17. An integrated classifier improves prognostic accuracy in non-metastatic gastric cancer.
Xing X; Jia S; Leng Y; Wang Q; Li Z; Dong B; Guo T; Cheng X; Du H; Hu Y; Feng Q; Lian S; Luan F; Ma X; Li Z; Ni M; Li Z; Ji J
Oncoimmunology; 2020 Aug; 9(1):1792038. PubMed ID: 32939321
[TBL] [Abstract][Full Text] [Related]
18. Increased PD-1-positive macrophages in the tissue of gastric cancer are closely associated with poor prognosis in gastric cancer patients.
Kono Y; Saito H; Miyauchi W; Shimizu S; Murakami Y; Shishido Y; Miyatani K; Matsunaga T; Fukumoto Y; Nakayama Y; Sakurai C; Hatsuzawa K; Fujiwara Y
BMC Cancer; 2020 Mar; 20(1):175. PubMed ID: 32131763
[TBL] [Abstract][Full Text] [Related]
19. Prognostic analysis of stage III gastric cancer after curative surgery according to the newest TNM classification.
Wei J; Yao T; Wang Y; Li L; Pan C; Zhang N
Clin Transl Oncol; 2019 Feb; 21(2):232-238. PubMed ID: 29968135
[TBL] [Abstract][Full Text] [Related]
20. Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer.
Su Y; Lin L; Zhang J; Jiang Y; Pan C; Sun L; Duan J; Liao W
Mol Med Rep; 2015 Oct; 12(4):5771-9. PubMed ID: 26239822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
